HT Amplifies Weight Loss With Tirzepatide in Menopause
'While previous studies, including our own, have demonstrated enhanced weight loss with hormone therapy in women using semaglutide, no prior data existed on tirzepatide,' senior author Maria Daniela Hurtado, MD, of the Division of Endocrinology, Diabetes, and Metabolism, at the Mayo Clinic, Jacksonville, Florida, told Medscape Medical News.
'This study addresses that gap and suggests that hormone therapy use is associated with a 35% greater total body weight loss compared to nonusers, suggesting a potential synergistic effect,' she said.
The study was presented at ENDO 2025, The Annual Meeting of the Endocrine Society.
In a previous study published in the journal Menopause , Hurtado and colleagues reported that menopausal women on HT who were treated with semaglutide had significantly greater improvements in weight loss and waist circumference than those not receiving HT.
In the current retrospective cohort study, the researchers sought to determine if the effects of the dual agonist glucose-dependent insulinotropic peptide (GIP)/ GLP-1 receptor agonist tirzepatide were likewise improved with HT in postmenopausal women.
Hurtado, along with first author Regina Castaneda, MD, and colleagues, evaluated data on 400 postmenopausal women who had been prescribed tirzepatide for the treatment of overweight or obesity for at least 12 months, either with or without concurrent HT.
Types of menopause HT used by the study participants were either transdermal or oral estrogen, with or without progesterone.
For the propensity score analysis, 120 of the patients were matched 1:2 based on those who were (n = 40) and were not receiving HT (n = 80). The groups were matched according to baseline characteristics and adiposity-related comorbidities, with a mean age of 56 years and 57 years, and mean BMI of 34 and 33, respectively.
Patients in both groups had median follow-up of 18 months, and as of the last follow-up, those in the HT group had a significantly greater total body weight loss compared with those not in the HT group (17% vs 14%; P = .01).
In addition, at the last follow-up, those receiving HT were much more likely to have achieved a 20% or higher total body weight loss than those not receiving HT (45% vs 18%; P = .001).
Does HT Address Lower Obesity Drug-Associated Weight Loss in Menopause?
Consistent with the semaglutide research, the weight loss observed among women on HT was not significantly higher than the typical weight loss observed in nonmenopausal women on tirzepatide — the difference was that women who were not on HT appeared at a disadvantage, Hurtado explained.
'Similar to our findings with semaglutide, women using menopause hormone therapy achieved weight loss comparable to that observed in pivotal tirzepatide trials, which predominantly included younger participants,' she said.
'In contrast, those not using hormone therapy experienced more modest weight loss, falling below expectations based on phase 3 trial data.'
While the findings support the theory that the menopause transition may impair response to weight-loss medications, 'this hypothesis remains unproven, and it is possible that the observed differences are attributable to aging alone, as advancing age is associated with reduced responsiveness to anti-obesity medications,' Hurtado said.
Estrogen/Tirzepatide Synergy?
The current findings, however, do add evidence supporting a menopausal hormone connection.
'Notably, the greater weight loss observed with concurrent hormone therapy use raises the possibility of a synergistic interaction between estrogen and tirzepatide,' Hurtado said.
Estrogen is already recognized to positively influence visceral fat distribution, thermogenesis, insulin sensitivity, and energy expenditure, she explained.
'It also enhances GLP-1 signaling pathways, which may potentiate tirzepatide's appetite-suppressing effects,' she said.
Likewise, 'absence of estrogen may reduce these synergistic effects, thereby attenuating the weight-loss response to GLP-1/GIP agonists.'
The study did not evaluate whether the common adverse events of tirzepatide are any different in patients receiving HT, however, the researchers are considering including that analysis in the study's final publication.
While the evidence suggests dual therapeutic benefits with obesity drugs and HT, 'the risks of hormone therapy must be individually assessed, and treatment decisions should follow a shared decision-making approach,' Hurtado noted.
Commenting on the study, Olena Klindukhova, MD, of the Medical College of Wisconsin, Milwaukee, emphasized that 'with menopause associated with significant weight gain, which can increase distress among women, it is reassuring that the addition of GLP-1 to HRT [hormone replacement therapy] helps to improve outcomes.'
Klindukhova, who comoderated the session, noted that a common concern with GLP-1s is the regaining of weight that has been shown to occur among nearly all patients upon drug discontinuation.
'We don't have data suggesting this is any different among menopausal women,' Klindukhova said.
The findings nevertheless suggest that 'hormone therapy and GLP-1s should be initiated sooner rather than later for symptomatic women in early menopause,'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Annual survey shows decrease in Spokane County homelessness from last year
Jul. 14—The number of homeless people in Spokane County fell by 10.6% last year. The findings are based on the 2025 point-in-time count conducted in January when teams fan out to count and question Spokane County's homeless population on a particular night. This year's count found 1,806 people living on the streets or in shelters. It was the second consecutive year that showed a decline While homelessness in Spokane dropped overall, the number of people living without shelter during January rose to 617 from 443 a year earlier, while the number of homeless people staying in shelters fell from 1,578 to 1,189. The annual point-in-time count, which the U.S. Department of Housing and Urban Development requires of counties receiving federal funding, had shown a steady increase in Spokane County homeless for much of the past decade until the past two years. As a snapshot during a single night of the year, the count cannot be extrapolated to what homelessness looks like year round and some experts question its reliability. Still, Mayor Lisa Brown touted the latest numbers as evidence her administration's approach to homelessness is working. "The big picture is the trend is in the right direction," she said Monday. During her tenure, Brown has shifted the city's focus on centralized emergency shelters to scattered sites across the city. Those moves, she said, are a cause of the overall decrease, and, the increase of unsheltered people. During the 2024 January count the Trent Resource and Assistance Center was still open. Its closure in November is one cause for the increase in unsheltered individuals surveyed. "I'm sure there were more shelter beds in 2024 than there were this year but there was not an equal rise in unsheltered populations, which I think means we're doing good work," argued Neighborhood, Housing, and Human Services division director Dawn Kinder. Of those surveyed during the 2025 count, 43% of adults reported they had severe mental illness and 52% of adults reported drug addiction. During a Monday presentation to the Spokane City Council, councilman Jonathan Bingle argued the city does not address these issues to the same degree they do housing. "We are regularly told this is a housing problem. And I don't disagree that there's a serious housing component to this. But when I see this data that means at a bare minimum we have 700 folks struggling with something pretty serious," he said. "I would like to see a little bit more balance in our conversations. Not just housing-focused because there is a lot more to this." Kinder defended the administration's housing-first policies as the only way for homeless individuals to receive effective treatment. "We are struggling with mental health and addiction and a myriad of challenges. But expecting somebody to get clean and sober while unhoused or have reliable treatment for mental health unhoused is a bit of a stretch," she said. "So is it more than housing? Yes. But can we get somebody completely healthy and stable without housing? No." The count also found 70% of respondents last became homeless while living in Spokane County. An additional 14% became homeless from somewhere within Washington State. Brown said the results are evidence against beliefs that many of Spokane's unhoused come from elsewhere in the country. "I don't buy the narrative that Spokane is somehow a magnet for the unhoused. I think a city in the urban center of a very rural region that has health care services, education services and potential employment is going to be a place where a lot of people end up," she said. Asked what she would say to Spokane residents who might not believe homelessness is decreasing, the mayor said: "People are still going to see homeless people" on the street even if the population in shelters is decreasing. "Nothing about the (count) suggests we've solved the crisis," added Kinder. "But we are making really strategic investments to try and address those who are unsheltered."
Yahoo
an hour ago
- Yahoo
Urgent warning for parents: Deadly nicotine poisonings in kids are skyrocketing
The number of young children sickened after getting their little hands on nicotine products like pouches and vape e-liquids has skyrocketed in recent years. From 2010 through 2023, U.S. poison centers reported 134,663 cases of nicotine poisonings among kids under age 6, according to a study published Monday in Pediatrics, a journal of the American Academy of Pediatrics. Nearly all occurred at home. The cases included exposures to nicotine pouches, chewing tobacco, regular cigarettes, vapes and nicotine replacement products like gum and lozenges. But it's nicotine pouches, like the wildly popular Zyn, that are behind the most significant rise in accidental nicotine poisonings among young kids. The new research found that the rate of poisonings involving nicotine pouches among kids under 6 rose from 0.48 per 100,000 children in 2020 to 4.14 per 100,000 in 2023. That's an increase of 763% in just three years — a startling finding that correlates with a surge in sales of nicotine pouches. Nicotine pouches — which users tuck between their lip and gum and later discard — can contain as much as 6 milligrams of nicotine, a stimulant, and have been promoted as tobacco-free, spit-free and hands-free alternatives to cigarettes and chewing tobacco. They are not, however, approved by the Food and Drug Administration as nicotine replacement products used to help quit smoking. Philip Morris, which owns Zyn, said in a statement that 'Zyn's packaging is designed to be child resistant.' A 2021 study from the Centers for Disease Control and Prevention's Office on Smoking and Health (one of several public health groups dismantled under the Trump administration) found that sales of nicotine pouches rose dramatically in the past decade, from $709,000 in 2016 to $216 million by mid-2020. 'It was just a matter of time before they fell into the hands of younger kids,' said Dr. Molly O'Shea, a Michigan pediatrician and spokesperson for the American Academy of Pediatrics. 'It's unfortunate, but not shocking.' Nicotine is a chemical that's highly toxic and could easily exceed a fatal dose in small children, according to a 2013 study. The chemical increases heart rate and blood pressure, and could lead to nausea, vomiting or even coma, the study authors wrote. Most cases included in the new research weren't serious enough to warrant medical attention. But 39 children had significant side effects, like trouble breathing and seizures, said Natalie Rine, an author of the new study and director of the Central Ohio Poison Center at Nationwide Children's Hospital in Columbus. Most nicotine poisoning cases, 76%, were babies and toddlers under age 2. Two children, a 1-year-old boy and another boy about a year and a half old, died after ingesting liquid nicotine used in vapes. 'It's good that the majority of kids in the study actually did pretty well. Most kids had either minor symptoms or no symptoms and didn't require any medical management,' Rine said. 'But two deaths is a lot, especially for something considered a preventable death.' The study 'adds to concerns about the health risks that nicotine pouches pose to kids,' Yolonda Richardson, president of the Campaign for Tobacco-Free Kids, said in a statement. 'It's critical that we educate parents, childcare providers and healthcare providers about the health risks of these products, including poisoning.' Richardson was not involved with the new research. Kids are curious by nature. Babies and toddlers in particular explore their worlds by putting things in their mouth. And they're masters at breaking into drawers and cabinets to find new 'toys.' Many canisters of nicotine pouches are not equipped with child-resistant packaging. They taste good, too. Mint and fruit flavors are almost always added. O'Shea said it's critical that all nicotine products are placed far out of reach of children. 'That doesn't mean in your purse, in your back pocket or on the counter,' she said. 'It means locked away.' It's not just parents and other adult caregivers who must be mindful of their nicotine products. An April study from the Keck School of Medicine of the University of Southern California found the use of nicotine pouches among high school students nearly doubled between 2023 and 2024. 'It's easy for a teenager to be using this product and have parents be unaware,' O'Shea said. 'It's important for parents to be talking with their teenagers about products like this and having open dialogue in a nonjudgmental way in order to ascertain any risk.' Rine also recommends adding the national poison control number to cellphones: 1-800-222-1222. This article was originally published on
Yahoo
an hour ago
- Yahoo
The Dire Wolf Company's Next Target? A Giant Flightless Bird
It has taken no end of imagination for Sir Peter Jackson, the Academy Award winning—and, not incidentally, knighted—director of the Lord of the Rings and Hobbit films, to produce his entire body of cinematic work. It's a quality Jackson has had since he was a small child, when he would conjure up visions of the future. 'When I was a kid [I dreamed of] personal jet packs and flying cars and things,' Jackson said in a recent conversation with TIME. 'One of those other things I always dreamed of was to be able to bring back extinct species.' No-go on the jet packs and the flying cars. But the business of de-extinction? That's very much happening. In April, the Dallas-based biotech company Colossal Biosciences announced that it had successfully brought back the dire wolf, an animal whose howl had not been heard on Earth since the last member of the species vanished more than 10,000 years ago. Three young dire wolves currently live on a 2,000-acre preserve in an undisclosed location to protect them from the media and curiosity-seekers, and Colossal aims to produce more of the animals, with the ultimate goal of perhaps rewilding the species. Read more: The Return of the Dire Wolf The company is not stopping there. Colossal also wants to bring back the dodo, the woolly mammoth, the Tasmanian tiger—or thylacine—and more. The goal is both to increase genetic diversity and to hone genetic editing techniques to fortify existing but threatened species. Now, Colossal has announced one more species to add to its growing menagerie: the emu-like moa, a giant flightless bird that stood up to 12 ft. (3.6 m) tall, tipped the scales at more than 500 lbs (230 kg), and once ranged across New Zealand, before it was hunted to extinction by humans about 600 years ago. Like the moa, Jackson is a native New Zealander; 'I am a very proud kiwi,' he says. He is also a Colossal investor and acted as intermediary and facilitator bringing the company into partnership on the moa project with the Ngāi Tahu Research Center, a group that was founded in 2011 to foster intellectual development and conduct scientific studies for and by the Ngāi Tahu tribe of the Indigenous Māori people. 'Some of those iconic species that feature in our tribal mythology, our storytelling, are very near and dear to us,' says Ngāi Tahu archaeologist Kyle Davis, who is working on the moa de-extinction project. 'Participation in scientific research, species management, and conservation has been a large part of our activities.' 'This is completely a Māori initiative,' adds Ben Lamm, CEO and co-founder of Colossal. 'We feel like the Colossal team is an extension of the research center and the Māori.' Bringing back the moa would have implications not only for the species itself but for the environment it once inhabited and could again. The bird was what is known as a cornerstone species, one whose grazing and browsing helped prune and shape the jungle flora. Moas were also prolific dispersers of seeds from the plants they ate. The loss of the species not only eliminated that forest-restoring function, but also led to the related extinction of the Haast's eagle, which relied almost exclusively on the moa as prey. Restoring the moa would not bring the eagle back but could help at least partly restore the primal New Zealand woodlands. Bringing back the moa is of a piece with Colossal's other work, which seeks not only to restore vanished species, but to prevent related ones from slipping over the event horizon of extinction. Genetic engineering mastered in the dire wolf project, for example, is being used to edit greater diversity into the genome of the endangered red wolf. Knowledge gained in the effort to bring back the thylacine could similarly help preserve the related northern quoll. 'There are some species of birds on the South Island of New Zealand that are endangered due to the fact that they have reduced gene pools,' says Paul Scofield, senior curator of natural history at Canterbury Museum, author of 20 papers on the moa genome, and one of the scientists working on the de-extinction project. 'Some of the technology that Colossal is working with is very applicable to them.' Read more: Scientists Have Bred Woolly Mice on Their Journey to Bring Back the Mammoth That technology is decidedly challenging. De-extincting the dire wolf involved sequencing ancient DNA collected from fossil specimens and then rewriting the genome of cells from a gray wolf to resemble the extinct species with the lost ancient genes. The edited nucleus was then inserted into a domestic dog ovum whose own nucleus had been removed. That ovum was allowed to develop into an embryo in the lab and then implanted into the womb of a surrogate domestic dog, which carried the dire wolf pup to term.' Bringing back the extinct moa is harder since the incubating will be done outside the body, inside an egg. The first step in this work once again calls for sequencing the genome of the extinct target species and once again turning to a closely related living species—either the tinamou or the emu—for help. Colossal scientists will extract primordial germ cells—or cells that develop into egg and sperm—from a tinamou or emu embryo and rewrite their genome to match key features of the moa. Those edited cells will then be introduced into another embryonic tinamou or emu inside an egg. If all goes to plan, the cells will travel to the embryo's gonads, transforming them so that the females produce eggs and the males produce sperm not of the host species but of the moa. The result will be an emu or tinamou that hatches, grows up, mates, and produces eggs containing moa chicks. 'We've had some pretty big successes so far,' says Lamm. 'We have a breeding colony of tinamous but not emus, but have access to emu eggs through the many breeders out there." None of this means that the work is remotely done. Lamm concedes it could be up to ten years before a moa once again walks New Zealand—though it could come sooner. 'I'd rather underpromise and overdeliver,' he says. For now, Colossal and the Ngāi Tahu Research Center are still working to sequence the moa genome, and to do that they have to get their hands on more DNA samples. Museum specimens of moa remains satisfy some of that demand, but DNA degrades significantly over the centuries and what can't be harvested from private collections has to be dug up in field excavations—with a special eye to long, DNA-rich moa bones like the femur and tibia. 'There are a couple of really significant fossil sites, particularly one in North Canterbury, about an hour north of Christchurch,' says Scofield. 'So far we've sampled more than 60 individuals.' If those don't prove sufficient, he adds, 'we will have to go out and dig some more holes.' None of this comes cheap, and while Lamm does not disclose the exact funding for the moa de-extinction project, he does say it is an eight-figure sum. 'I saw the new Jurassic World movie and someone in it says it costs $72 million to bring back one animal,' he says. 'I was like, 'That's probably accurate.'' That up-front expenditure could pay off handsomely down the line, boosting ecotourism to New Zealand and benefiting Colossal's basic research, which is already showing for-profit potential. So far, Colossal has spun off two new companies: One, called Breaking, uses engineered microbes and enzymes to break down plastic waste. The other, Form Bio, provides AI and computational biology platforms for drug development. But it's the intangibles—the wonder of midwifing a long-extinct species back to the global family of extant ones—that is Colossal's and the Māori's most transcendent work. 'This has an excitement value to it that movies don't have,' says Jackson. 'When I see a living moa for the first time I'm going to be absolutely amazed beyond anything I've ever felt.' Write to Jeffrey Kluger at
